Home Uncategorized FDA approves new treatment for VAP

FDA approves new treatment for VAP

Author(s):

On June 3, the FDA approved a new indication for Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Read more at fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here